Kirkland & Ellis LLP
01/13/2026 | Press release | Distributed by Public on 01/13/2026 16:22
Kirkland Advises TerSera Therapeutics on Sale of Infusion Specialty Therapies Business Unit to ESTEVE
Kirkland & Ellis advised TerSera Therapeutics LLC, a biopharmaceutical company with a focus on oncology and rare diseases, on an agreement whereby ESTEVE will acquire TerSera's Infusion Specialty Therapies Business Unit (IST). TerSera's IST business unit includes two specialty medications, Prialt® (ziconotide intrathecal infusion) and Quzyttir® (cetirizine hydrochloride injection). The transaction is expected to close in the first quarter of 2026, subject to regulatory clearances.
Read the transaction press release
The Kirkland team included corporate lawyers Kyle McHugh, Ben Vizvary, Chris Thomas and Emily Binger; technology & intellectual property lawyers Amber Harezlak, Frank Gallina and Daniel Lewis; debt finance lawyers Jocelyn Hirsch and Patrick Loughery; and tax lawyer Polina Liberman.
Kirkland & Ellis LLP published this content on January 13, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on January 13, 2026 at 22:22 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]